

LGALS8 Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP17988b**Specification****LGALS8 Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [O00214](#)**LGALS8 Antibody (C-term) Blocking Peptide - Additional Information**

Gene ID 3964

Other NamesGalectin-8, Gal-8, Po66
carbohydrate-binding protein, Po66-CBP,
Prostate carcinoma tumor antigen 1,
PCTA-1, LGALS8**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

LGALS8 Antibody (C-term) Blocking Peptide - Protein InformationName LGALS8 ([HGNC:6569](#))**Function**Beta-galactoside-binding lectin that acts as a sensor of membrane damage caused by infection and restricts the proliferation of infecting pathogens by targeting them for autophagy (PubMed:<http://www.uniprot.org/citations/22246324> target="_blank">22246324, PubMed:<http://www.uniprot.org/ci>**LGALS8 Antibody (C-term) Blocking Peptide - Background**

This gene encodes a member of the galectin family. Galectins are beta-galactoside-binding animal lectins with conserved carbohydrate recognition domains. The galectins have been implicated in many essential functions including development, differentiation, cell-cell adhesion, cell-matrix interaction, growth regulation, apoptosis, and RNA splicing. This gene is widely expressed in tumoral tissues and seems to be involved in integrin-like cell interactions. Alternatively spliced transcript variants encoding different isoforms have been identified.

LGALS8 Antibody (C-term) Blocking Peptide - References

Cludts, S., et al. Anticancer Res. 29(12):4933-4940(2009)
Cueni, L.N., et al. Exp. Cell Res. 315(10):1715-1723(2009)
Yoshida, H., et al. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 65 (PT 5), 512-514 (2009)
Massardo, L., et al. Lupus 18(6):539-546(2009)
Savin, S., et al. Med. Oncol. 26(3):314-318(2009)

tations/28077878" target="_blank">28077878). Detects membrane rupture by binding beta-galactoside ligands located on the luminal side of the endosome membrane; these ligands becoming exposed to the cytoplasm following rupture (PubMed:22246324, PubMed:28077878). Restricts infection by initiating autophagy via interaction with CALCOCO2/NDP52 (PubMed:22246324, PubMed:28077878). Required to restrict infection of bacterial invasion such as *S.typhimurium* (PubMed:22246324). Also required to restrict infection of Picornaviridae viruses (PubMed:28077878). Has a marked preference for 3'-O-sialylated and 3'-O-sulfated glycans (PubMed:21288902).

Cellular Location

Cytoplasmic vesicle. Cytoplasm, cytosol

Tissue Location

Ubiquitous. Selective expression by prostate carcinomas versus normal prostate and benign prostatic hypertrophy

LGALS8 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)